Phase 0/I Study of AMG 232 Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2018
At a glance
- Drugs AMG 232 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Pharmacokinetics
- 10 Jan 2018 Planned number of patients changed from 92 to 86.
- 10 Jan 2018 Planned initiation date changed from 27 Oct 2017 to 27 Jan 2018.
- 13 Apr 2017 New trial record